Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Japan Pain Relief Medication Market

ID: MRFR/MED/49333-HCR
200 Pages
Nidhi Mandole
Last Updated: April 02, 2026

Japan Pain Relief Medication Market Research Report: Size, Share, Trend Analysis By Medication Type (Non-Steroidal Anti-Inflammatory Drugs, Acetaminophen, Opioids, Adjuvant Analgesics), By Formulation Type (Tablets, Capsules, Liquid, Topical), By Route of Administration (Oral, Topical, Injectable, Transdermal) and By Therapeutic Area (Chronic Pain, Acute Pain, Postoperative Pain, Cancer Pain) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Japan Pain Relief Medication Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Construction, BY Type (USD Million) | |
      1. 4.1.1 Non-Steroidal Anti-Inflammatory Drugs | |
      2. 4.1.2 Acetaminophen | |
      3. 4.1.3 Opioids | |
      4. 4.1.4 Adjuvant Analgesics |
    2. 4.2 Construction, BY Formulation Type (USD Million) | |
      1. 4.2.1 Tablets | |
      2. 4.2.2 Capsules | |
      3. 4.2.3 Liquid | |
      4. 4.2.4 Topical |
    3. 4.3 Construction, BY Route of Administration (USD Million) | |
      1. 4.3.1 Oral | |
      2. 4.3.2 Topical | |
      3. 4.3.3 Injectable | |
      4. 4.3.4 Transdermal |
    4. 4.4 Construction, BY Therapeutic Area (USD Million) | |
      1. 4.4.1 Chronic Pain | |
      2. 4.4.2 Acute Pain | |
      3. 4.4.3 Postoperative Pain | |
      4. 4.4.4 Cancer Pain 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Construction | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Johnson & Johnson (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Pfizer (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Bayer (DE) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 GlaxoSmithKline (GB) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 AbbVie (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 AstraZeneca (GB) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Sanofi (FR) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Novartis (CH) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Teva Pharmaceutical Industries (IL) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 JAPAN MARKET ANALYSIS BY TYPE |
    6. 6.3 JAPAN MARKET ANALYSIS BY FORMULATION TYPE |
    7. 6.4 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    8. 6.5 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA |
    9. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION |
    10. 6.7 RESEARCH PROCESS OF MRFR |
    11. 6.8 DRO ANALYSIS OF CONSTRUCTION |
    12. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION |
    13. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION |
    14. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION |
    15. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE) |
    16. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million) |
    17. 6.14 CONSTRUCTION, BY FORMULATION TYPE, 2024 (% SHARE) |
    18. 6.15 CONSTRUCTION, BY FORMULATION TYPE, 2024 TO 2035 (USD Million) |
    19. 6.16 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
    20. 6.17 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million) |
    21. 6.18 CONSTRUCTION, BY THERAPEUTIC AREA, 2024 (% SHARE) |
    22. 6.19 CONSTRUCTION, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million) |
    23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    24. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    25. 7.2 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million) | |
      2. 7.2.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
      4. 7.2.4 BY THERAPEUTIC AREA, 2025-2035 (USD Million) |
    26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.3.1 |
    27. 7.4 ACQUISITION/PARTNERSHIP | |

Japan Construction Market Segmentation

Construction By Type (USD Million, 2025-2035)

  • Non-Steroidal Anti-Inflammatory Drugs
  • Acetaminophen
  • Opioids
  • Adjuvant Analgesics

Construction By Formulation Type (USD Million, 2025-2035)

  • Tablets
  • Capsules
  • Liquid
  • Topical

Construction By Route of Administration (USD Million, 2025-2035)

  • Oral
  • Topical
  • Injectable
  • Transdermal

Construction By Therapeutic Area (USD Million, 2025-2035)

  • Chronic Pain
  • Acute Pain
  • Postoperative Pain
  • Cancer Pain

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions